



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/EA/2025-26/158

January 12, 2026

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code - 532523</b>	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol - BIOCON</b>
--	---

Dear Sir/Madam,

**Subject: Qualified Institutions Placement of equity shares of face value ₹ 5 each (“Equity Shares”) (such placement, the “Issue”) by Biocon Limited (the “Company”) under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and Sections 42, 23(1)(b) and 62(1)(c) of the Companies Act, 2013, as amended.**

We wish to inform you that pursuant to the approval accorded by the Board of Directors of the Company (the “**Board**”), at its meeting held on December 06, 2025, and the shareholders of the Company, pursuant to the special resolution passed at the Extra-ordinary General Meeting (“**EGM**”) of the Company held on December 31, 2025, the Fund Raising Committee (the “**Committee**”) has at its meeting held today i.e. January 12, 2026, *inter alia*, passed the following resolutions:

- Authorizing the opening of the Issue today, i.e. January 12, 2026;
- Approving the floor price for the Issue, being ₹ 387.74 per Equity Share (“**Floor Price**”), based on the pricing formula as prescribed under Regulation 176 of the SEBI ICDR Regulations; and
- Approving and adopting the preliminary placement document dated January 12, 2026, together with the application form in connection with the Issue.

We further wish to inform you that the Fund Raising Committee has fixed the ‘relevant date’ for the purpose of the Issue, in terms of Regulation 171 of the SEBI ICDR Regulations, as January 12, 2026, and accordingly the Floor Price in respect of the Issue has been determined, based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations, as ₹ 387.74 per Equity Share.

Pursuant to Regulation 176(1) of the SEBI ICDR Regulations, as amended and in accordance with the approval of the shareholders accorded through a special resolution passed at the aforesaid EGM on December 31, 2025, the Company may at its discretion offer a discount of not more than 5% on the floor price for the Issue.

The Issue price will be determined by the Company in consultation with the book running lead managers appointed for the Issue.

The meeting of the Fund Raising Committee commenced at 4:30 PM (IST) and concluded at 4:40 PM (IST).



In relation to the qualified institutions placement, we will file the preliminary placement document with your office today.

Further, pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Code of Conduct for Prevention of Insider Trading of the Company for regulating, monitoring and reporting of trading by insiders, the trading window for dealing in the securities of the Company has already been closed till further notice, for the purpose of the Issue.

We request you to kindly take this on records, and the same be treated as compliance under Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Copy of this intimation is being also made available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking you,

Yours faithfully,

For **Biocon Limited**

---

**Rajesh U. Shanoy**  
**Company Secretary and Compliance Officer**  
**ICSI membership number: A16328**